Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Source: CNBC Top Stories | Published: October 28, 2025, 8:32 pm | Read Original

Strong Bullish 100.0

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.

Read Source Login to use Pulse AI

Pulse AI Analysis

Pulse analysis not available yet. Click "Get Pulse" above.

This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Glideslope AI

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.

CNBC Top Stories • Oct 28, 2025 • Found on Glideslope.ai

Post hash: 3tsrndf • glideslope.ai/post/3tsrndf

Sentiment

Strong Bullish • Score: 100.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

" selected code.

Pulse AI Analysis

Related Insights

More Like This

Weight-loss drugs are spreading across the world

More deadly U.S. strikes on boats allegedly carrying drugs in the Pacific

US kills 14 in strikes on four alleged drug boats in Pacific

Spin Cycle: The War On Trump’s War On Drugs

Novartis to acquire Avidity Biosciences for about $12B

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports